CTPI 2

Product Description

CTPI 2 is a selective mitochondrial citrate transporter (SLC25A1) inhibitor with a K_D of 3.5 μM. CTPI 2 inhibits the proliferation of H1299 cells in a SLC25A1-dependent manner. It also re-sensitizes T1, T2, and T4 cells to Cisplatin (Cat. No. 2251). CTPI 2 inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC). In high-fat diet fed mice CTPI 2 regulates glycolysis, prevents steatohepatitis and normalizes glucose tolerance and insulin sensitivity. CTPI 2 influences the inflammatory pathway by inhibiting IL-6 and TNFα production and M1 macrophage polarization.

Solubility

Preparing Stock Solutions for CTPI 2

The following data is based on the product molecular weight 356.74

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.80 mL	14.02 mL	28.03 mL
5 mM	0.56 mL	2.80 mL	5.61 mL
10 mM	0.28 mL	1.40 mL	2.80 mL
50 mM	0.06 mL	0.28 mL	0.56 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Fernandez The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018 PMID: 29651165
• Batchuluun Lipogenesis inhibitors: therapeutic opportunities and challenges. Nat.Rev.Drug Discov. 2022 PMID: 35031766
• Tan Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH. Cell Death Differ. 2020 PMID: 31959914